Clinical trials: GLP - 1
Obesity, Chronic Kidney Diseases
Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease
The goal of this clinical trial is to exploring the changes in 24-hour urinary protein and renal function in obese patients with kidney disease after the application of sodium glucose cotransporter 2 inhibitors (SGLT2i) and…
- Trial name
- NCT06344247
- Testing
- RAS inhibitors：Losartan®️/Valsartan®️, dapagliflozin：Forxiga®️, simagliptin：Forxiga®️
- Where
- China
- Volunteers
- 48 people
- Sponsor
- RenJi Hospital
Bariatric Surgery (Gastric Bypass)
Can Postprandial Reactive Hypoglycaemia be Reduced in Patients After Roux-en-Y Gastric Bypass With a Low Carbohydrate Diet?
Roux-en-Y gastric bypass (RYGB) accelerates nutrient delivery to the small intestine causing higher peak blood glucose concentration early after meal intake.
- Trial name
- NCT02665715
- Testing
- Low carbohydrate meals, Standard carbohydrate meals
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Amirsalar Samkani
Myocardial Infarction
GLP-1 on Non-ST-Segment Elevation Myocardial Infarction
The investigators planned to evaluate the effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction (NSTEMI).
- Trial name
- NCT02577848
- Testing
- GLP-1
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese PLA General Hospital
Glucose Metabolism Disorders
The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D
Delineation of the role of glucagon-like peptide-1 receptor signalling in the glucose-lowering effect of metformin during meal ingestion in patients with type 2 diabetes.
- Trial name
- NCT03246451
- Testing
- Metformin, Saline, Exendin (9-39)
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Vagotomy, Truncal
Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects
The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of glucose and Glucagon-like peptide-1 (GLP-1) in respect to insulin secretion.
- Trial name
- NCT01176760
- Testing
- Dipeptidyl peptidase 4 (DPP 4) inhibitor, oral glucose
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus, Type 2, Insulin Resistance
New Frontiers on Bariatric Surgical Procedures: Classical Bypass for Type-2 Diabetic Patients With Obesity Grade I
Bariatric surgery leads to remission of type 2 diabetes in morbid obese patients in 80% (Roux-en-Y gastric bypass)to 90% (biliopancreatic diversion and duodenal switch) of cases.
- Conditions
- Diabetes Mellitus, Type 2, Insulin Resistance, Obesity
- Trial name
- NCT00566189
- Testing
- Roux-en-Y Bypass Gastroplasty
- Where
- Brazil
- Volunteers
- 36 people
- Sponsor
- University of Campinas, Brazil
Diabetes Type 2
"Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients"
The purpose of this study is to demonstrate the secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets with different nutritional compounds (fat, protein and carbohydrate food) in drug näive…
- Trial name
- NCT00881543
- Testing
- Dipeptidyl Peptidase IV inhibitors
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- University of Sao Paulo General Hospital
Ischemic Stroke
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
Endovascular thrombectomy (EVT) is a procedure that improves recovery for people who suffer from a stroke by removing blood clots from large blood vessels in the brain.
- Trial name
- LEAST (NCT07511543)
- Testing
- Semaglutide
- Volunteers
- 100 people
- Sponsor
- Population Health Research Institute
GLP-1, Obesity &Amp; Overweight
Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults
Obesity is a chronic condition linked to numerous health risks and affects more than one billion people worldwide. While pharmacological treatments such as incretin-based therapies are available, they may have side effects, are…
- Conditions
- GLP-1, Obesity &Amp; Overweight, Dietary Supplement
- Trial name
- NCT07240246
- Testing
- Intervention: Dietary Supplement with Plant Extracts
- Where
- Austria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation
Kidney Disease, Chronic, Diabetes
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population.
- Conditions
- Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)
- Trial name
- GUARD-1 (NCT07017270)
- Testing
- Semaglutide Pen
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Unity Health Toronto
Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).
Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)
Myocardial infarction (MI) causes loss of myocytes and may lead to loss of ventricular function, morbidity and mortality. The most effective therapy is early reperfusion of the ischemic myocardium by percutaneous coronary…
- Trial name
- EXAMI (NCT01254123)
- Testing
- Exenatide infusion
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Amsterdam UMC, location VUmc
Myocardial Injury
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery.
- Trial name
- GLUMINS (NCT06324461)
- Testing
- Dulaglutide 0.75mg subcutaneous injection
- Where
- 3 sites in China
- Volunteers
- 372 people
- Sponsor
- The University of Hong Kong
Type 2 Diabetes
Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM
To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea
- Trial name
- NCT02887625
- Testing
- Pioglitazone plus exenatide, insulin glargine and insulin aspart
- Where
- Qatar
- Volunteers
- 410 people
- Sponsor
- Dr. Muhammad Abdulghani
Type 2 Diabetes
Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy
Purpose This study will examine the effect of the addition of Cycloset upon glucose metabolism (glycemic control including post prandial glucose metabolism) in individuals with inadequately controlled (HbA1c 7.5-10.0) type 2…
- Trial name
- NCT02299050
- Testing
- Cycloset
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2, Insulin Resistance
Characterization of the Incretinpathy in Type 2 Diabetes Initiated After Sixty Years Old
Type 2 diabetes (T2DM) is characterized by hyperglycemia, insulin resistance, absolute or relative insulin deficiency, hyperglucagonemia, increased hepatic glucose production, frequently accelerated gastric emptying and obesity.
- Trial name
- NCT00843232
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- University of Campinas, Brazil
Thirst, Water-Electrolyte Imbalance
Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake
The aim of this study is to elucidate whether GLP-1 analogues influence not only appetite but also thirst perception. It is hypothesized that GLP-1 analogues reduce fluid intake in healthy volunteers compared to Placebo.
- Trial name
- GATE (NCT03141632)
- Testing
- Dulaglutide
- Where
- Switzerland
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Appetite and General Nutritional Disorders, Hormone Replacement
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY
The purpose of this study is to determine the functional significance of sweet taste receptors in the secretion of GI satiety peptides by using a specific sweet taste receptor antagonist to block sweet taste perception in the gut.
- Trial name
- NCT01088841
- Testing
- lactisole
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Bipolar I Disorder, Bipolar II Disorder
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity
- Trial name
- OBOE-Mayo (NCT07213466)
- Testing
- Group Therapy Program, semaglutide, Phentermine-Topiramate
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Type 2 Diabetes Mellitus
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
Incretinbased treatment of patients with type 2 diabetes mellitus (T2DM) has increasing interest. The incretin glucagon-like peptide-1 (GLP-1) stimulates beta-cells to increased secretion and production of insulin.
- Trial name
- NCT00655603
- Testing
- Infusion of native hormones from the pancreas and gut (GLP-1)
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Obesity
Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss
Background: Obesity is an important public health concern. Surgery is effective but invasive and expensive, and some obese persons are not good surgical candidates.
- Trial name
- NCT05268627
- Testing
- Liraglutide
- Where
- 2 sites in Egypt
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Mansoura University